Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 16/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14368461 | 0.90 | CSNK1E (0.53) | CSNK1ECSNK1D | |
| SCHEMBL4041559 | 0.90 | CSNK1E (0.49) | CSNK1ECSNK1D | |
| SCHEMBL14393983 | 0.89 | CSNK1E (0.46) | CSNK1ECSNK1DNAMPT | |
| SCHEMBL14393987 | 0.88 | TRPV1 (0.52) | CSNK1ECSNK1D | |
| SCHEMBL4220262 | 0.88 | KMT2A (0.47) | CSNK1ECSNK1D | |
| SCHEMBL14368436 | 0.87 | CSNK1E (0.56) | CSNK1ECSNK1D | |
| SCHEMBL14368460 | 0.87 | CSNK1E (0.52) | CSNK1ECSNK1D | |
| SCHEMBL14368463 | 0.84 | CSNK1E (0.62) | CSNK1ECSNK1D | |
| SCHEMBL14368439 | 0.84 | CSNK1E (0.53) | CSNK1ECSNK1D | |
| SCHEMBL14368533 | 0.83 | CSNK1E (0.48) | CSNK1ECSNK1DNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436291-B1 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-01-14 | — | — | EP | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| EP-1436291-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | Aventis Pharma S.A. (FR) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003024967-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238734-A1 | JNK INHIBITORS | MAP3K7, MAPKAPK2, MAPK7 | CSNK1E 136/4885CSNK1D 134/4885NAMPT 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.